October 13, 2026 The post Avenzo Therapeutics Announces Oral Presentation of Phase 1 Data for VBC103 (AVZO-103), a Potentially Differentiated Nectin-4/TROP2 Bispecific Antibody-Drug Conjugate, by Partner VelaVigo at ESMO Asia Congress 2026 first appeared on Avenzo Therapeutics .
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules